Diplomat to Dispense DAKLINZA® for Hepatitis C Treatment
FLINT, Mich. – July 28, 2015 – The nation’s largest independent specialty pharmacy is named a preferred vendor for Bristol-Myers Squibb’s newly approved hepatitis C treatment DAKLINZA® (daclatasvir).
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is a preferred vendor to dispense DAKLINZA® (daclatasvir), a direct-acting antiviral drug that targets the different stages of the hepatitis C virus (HCV) lifecycle.
DAKLINZA® is indicated in combination with other products for the treatment of chronic hepatitis C virus (HCV) genotype 3 infection in adults, which may include other direct-acting antivirals, and is not effective if taken alone. DAKLINZA® is approved for patients with HCV genotype 3 infection and is used to treat adults with chronic infection of HCV.
Hepatitis C is a viral disease that causes inflammation of the liver, which can lead to diminished liver function or liver failure. Some individuals with chronic hepatitis C infection may develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly. According to the Centers for Disease Control and Prevention, approximately 2.7 million Americans are infected with HCV, approximately 10 percent are genotype 3. Unlike many other serious or chronic diseases, hepatitis C can be cured.
“DAKLINZA® has the potential to play a significant role in treating HCV,” said Gary Kadlec, president of Diplomat. “It could offer a new means of treatment or even a shorter treatment, and we are excited about that—about bringing relief to a wider patient population.”
Treatment with DAKLINZA® should be initiated and monitored by a physician experienced in the management of chronic hepatitis C.
DAKLINZA® is distributed by Bristol-Myers Squibb. Full prescribing information is available at http://www.kodc.or.kr/home/drug_info/readDownloadFile.do;jsessionid=C5A2DAD4B6EE55414F79E40385C244B1?kdcode=Z40000418&drugCd=B003301&type=eng.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Gary Rice, RPh, MS, MBA, CSP,
Vice President, Clinical Services
810.768.9863 | firstname.lastname@example.org
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO174 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…2 weeks ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm3 weeks ago